Author:
Fatehi Leili,Wolf Susan M.,McCullough Jeffrey,Hall Ralph,Lawrenz Frances,Kahn Jeffrey P.,Jones Cortney,Campbell Stephen A.,Dresser Rebecca S.,Erdman Arthur G.,Haynes Christy L.,Hoerr Robert A.,Hogle Linda F.,Keane Moira A.,Khushf George,King Nancy M. P.,Kokkoli Efrosini,Marchant Gary,Maynard Andrew D.,Philbert Martin,Ramachandran Gurumurthy,Siegel Ronald A.,Wickline Samuel
Abstract
Nanomedicine is yielding new and improved treatments and diagnostics for a range of diseases and disorders. Nanomedicine applications incorporate materials and components with nanoscale dimensions (often defined as 1-100 nm, but sometimes defined to include dimensions up to 1000 nm, as discussed further below) where novel physiochemical properties emerge as a result of size-dependent phenomena and high surface-to-mass ratio. Nanotherapeutics and in vivo nanodiagnostics are a subset of nanomedicine products that enter the human body. These include drugs, biological products (biologics), implantable medical devices, and combination products that are designed to function in the body in ways unachievable at larger scales. Nanotherapeutics and in vivo nanodiagnostics incorporate materials that are engineered at the nanoscale to express novel properties that are medicinally useful. These nanomedicine applications can also contain nanomaterials that are biologically active, producing interactions that depend on biological triggers. Examples include nanoscale formulations of insoluble drugs to improve bioavailability and pharmacokinetics, drugs encapsulated in hollow nanoparticles with the ability to target and cross cellular and tissue membranes (including the bloodbrain barrier) and to release their payload at a specific time or location, imaging agents that demonstrate novel optical properties to aid in locating micrometastases, and antimicrobial and drug-eluting components or coatings of implantable medical devices such as stents.
Publisher
Cambridge University Press (CUP)
Subject
Health Policy,General Medicine,Issues, ethics and legal aspects
Reference213 articles.
1. 135. National Institutes of Health, NIH Policy for Data and Safety Monitoring (NOT-98-084) (1998), available at (last visited August 24, 2012).
2. 209. NRC Research Strategy, supra note 29, at 50, 63.
3. 144. Resnik, and Sharp, , supra note 75, at 3.
4. The New Toxicology of Sophisticated Materials: Nanotoxicology and Beyond
5. 176. 5 U.S.C. Appendix 2 (1972).
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献